Product Development - Anaphylm™ (dibutepinephrine) Sublingual Film is being developed as the first non-device based, orally delivered epinephrine product candidate, showing clinical results comparable to auto-injectors for treating anaphylaxis [167]. - In March 2024, the pivotal clinical study for Anaphylm met its primary endpoint of epinephrine PK biocomparability with IM injection and autoinjectors, demonstrating safety and tolerability [173]. - The pivotal clinical study commenced in Q4 2023, incorporating FDA feedback on protocol design, sample size, and statistical analysis [171]. - Positive topline data from a temperature/pH study of Anaphylm showed no statistically significant difference in PK and PD results based on temperature and pH variability [174]. - In October 2024, positive topline data from the OASIS study showed a median time to complete symptom resolution of 12 minutes post-Anaphylm administration, compared to 74 minutes at screening baseline [177]. - The pediatric study for Anaphylm, involving 32 patients aged 7 to 17, reported consistent PK results with previous adult studies and no serious adverse events [180]. - Anaphylm's PK profile showed median Tmax maintained at 12 minutes, with rapid symptom resolution observed in 94% of subjects after allergen exposure [177]. - The company is focused on addressing large market opportunities with its complex molecule pipeline, including the Anaphylm and Adrenaverse™ platforms [167]. Regulatory Approvals - The FDA granted Fast Track designation for Anaphylm in March 2022, and the 505(b)(2) regulatory approval pathway was confirmed as acceptable [169]. - The FDA accepted the NDA submission for Anaphylm on June 16, 2025, with a PDUFA target action date of January 31, 2026 [181]. - The FDA confirmed that an advisory committee meeting would not be required for Anaphylm, streamlining the approval process [182]. - The company received positive pre-NDA feedback from the FDA, indicating no additional adult clinical trials would be necessary for the NDA submission [179]. - The company is pursuing regulatory strategies for Anaphylm outside the United States, including discussions with Health Canada and the EMA [181]. Financial Performance - The company generated $31,530 and $45,694 in revenue from its licensed product portfolio for the nine months ended September 30, 2025, and 2024, respectively [191]. - Total revenues for the three months ended September 30, 2025, decreased by 5%, or $735, compared to the same period in 2024, primarily due to decreases in license and royalty revenue [223]. - Manufacture and supply revenue increased by approximately 7%, or $796, for the three months ended September 30, 2025, driven by a $395 increase in Sympazan revenues and a $380 increase in Suboxone revenues [224]. - License and royalty revenue decreased by 52%, or $1,124, for the three months ended September 30, 2025, primarily due to the one-time recognition of deferred revenue of $1,227 from a terminated licensing agreement [225]. - Total revenues for the nine months ended September 30, 2025, decreased by 31%, or $14,164, compared to the same period in 2024, mainly due to decreases in license and royalty revenue and manufacture and supply revenue [228]. - License and royalty revenue for the nine months ended September 30, 2025, decreased by 82%, or $11,847, primarily due to the one-time recognition of deferred revenues of $11,544 from terminated licensing agreements [230]. Research and Development - R&D expenses are expected to remain significant as the company develops existing product candidates and identifies new opportunities [210]. - Research and development expenses decreased by 14%, or $739, for the three months ended September 30, 2025, primarily due to lower clinical trial costs associated with the Anaphylm program [236]. - R&D share-based compensation increased by $1,000, or 323%, primarily due to acceleration of compensation related to severance [239]. - R&D personnel costs increased by 10% or $464 for the nine months ended September 30, 2025, mainly due to one-time severance expenses [248]. - R&D expenses decreased by 9% or $1,367 for the nine months ended September 30, 2025, mainly due to a reduction in clinical trial costs associated with the Anaphylm program [246]. Cost Management - The company is managing costs in preparation for a potential decline in Suboxone revenue and focusing on regulatory activities for Anaphylm [213]. - Selling, General and Administrative expenses include costs related to executive compensation, legal fees, and market research [211]. - Selling, general and administrative expenses increased by 38% or $12,856 for the nine months ended September 30, 2025, primarily due to higher commercial spending of approximately $5,950 for Anaphylm launch and regulatory fees of approximately $4,310 [249]. Financing Activities - The company sold 7,457,627 shares of Common Stock under the ATM facility for net proceeds of approximately $21,261 for the nine months ended September 30, 2025 [256]. - The company completed a public offering of 21,250,000 shares at $4.00 per share, resulting in net proceeds of $79,900 after underwriting discounts [263]. - Net cash provided by financing activities rose to $101,957 thousand, up from $83,435 thousand in the prior year, driven by net proceeds from the public offering and higher ATM proceeds [267]. - The company expects to incur significant operating losses and negative cash flows for the foreseeable future, indicating a reliance on external financing to achieve its operating plan [270][271]. - The company has utilized existing cash and equivalents for product pipeline development and working capital, with no assurance that future funding will be available on reasonable terms [269]. Debt and Interest - Interest expense consists of costs on the outstanding balances of 13.5% Notes, payable quarterly [215]. - The company has substantial ongoing interest payments and principal repayments related to its 13.5% Notes starting in June 2026, with a significant portion of revenues dependent on a single customer, Indivior [273]. - Interest expense related to royalty obligations increased by 5%, or $74, for the three months ended September 30, 2025, compared to the same period in 2024 [234]. - Interest expense was $8,342 for the nine months ended September 30, 2025, compared to $8,343 for the same period in 2024 [250]. - Interest income and other income, net decreased by 69%, or $673, for the three months ended September 30, 2025, compared to the same period in 2024 [234]. Cash Position - The company had $129,063 in cash and cash equivalents as of September 30, 2025, providing liquidity for operating needs for at least the next twelve months [254]. - For the nine months ended September 30, 2025, net cash used for operating activities increased to $(43,963) thousand from $(29,270) thousand in the prior year, primarily due to a net loss increase of $24,842 thousand [264][265]. - Interest income and other income, net increased to $3,115 for the nine months ended September 30, 2025, from $2,703 in 2024, primarily due to an ERTC credit received [253].

Financial Performance - Rental revenue for the three months ended September 30, 2025, was $37,036,000, an increase of 5.4% from $34,175,000 in the same period of 2024[164]. - Net income attributable to common stockholders per share for the three months ended September 30, 2025, was $(0.45), compared to $0.14 in the same period of 2024[164]. - Total revenue for Q3 2025 was $37.2 million, an increase of $2.9 million (8.5%) from $34.3 million in Q3 2024, primarily due to acquisitions[185]. - Net loss for Q3 2025 was $5.1 million, a decrease of $8.5 million from net income of $3.4 million in Q3 2024[197]. - Total revenue for the nine months ended September 30, 2025 was $109.8 million, an increase of $6.2 million (6.0%) from $103.6 million in the same period in 2024[200]. - Funds from Operations (FFO) attributable to common stockholders increased to $14,530 thousand in Q3 2025, up from $13,731 thousand in Q3 2024, representing a growth of 5.8%[248]. - Adjusted EBITDAre for the three months ended September 30, 2025, was $25,714 thousand, compared to $24,002 thousand for the same period in 2024, reflecting a year-over-year increase of 7.1%[251]. Debt and Liquidity - Total debt as of September 30, 2025, was $709,635,000, an increase from $646,131,000 as of December 31, 2024[166]. - The weighted average interest rate on total debt increased to 4.06% as of September 30, 2025, compared to 3.75% as of December 31, 2024[166]. - The company has unutilized borrowing capacity under the revolver component of the Credit Facility of $171 million as of November 3, 2025[174]. - The company entered into an Amended and Restated Credit Facility on October 8, 2025, consisting of a $350 million Term Loan A, a $150 million Term Loan B, and a $400 million Revolver[225]. - The weighted average term of the company's debt, including the drawn Revolver component, was 4.4 years as of the closing of the Amended and Restated Credit Facility[230]. - The company expects to satisfy its liquidity needs through cash flow from operations, debt financing, and sales of additional equity securities[219]. Acquisitions and Investments - The company completed the acquisition of a five-property portfolio for a total purchase price of $69.6 million, with an aggregate of 486,598 leasable square feet and annualized base rent of $6.3 million[168][169]. - The company has an interest in an unconsolidated joint venture that owns two healthcare facilities[151]. - The company’s strategy includes investing in healthcare properties that provide attractive returns relative to the cost of capital[148]. Expenses and Impairments - General and administrative expenses for Q3 2025 were $4.9 million, up $0.5 million (11.4%) from $4.4 million in Q3 2024, mainly due to increased corporate expenses[186]. - Operating expenses for Q3 2025 were $8.2 million, an increase of $0.8 million (10.8%) from $7.4 million in Q3 2024, driven by acquisitions[187]. - Depreciation expense for Q3 2025 was $11.2 million, up $1.2 million (12.0%) from $10.0 million in Q3 2024, reflecting the impact of acquisitions[189]. - Interest expense for Q3 2025 was $8.2 million, an increase of $1.0 million (13.9%) from $7.2 million in Q3 2024, due to higher borrowings and interest rates[191]. - The company recognized an impairment loss of $6.3 million related to its Aurora, Illinois facility during the nine months ended September 30, 2025[171]. - The company reported an impairment of investment property amounting to $6,281 thousand for the three months ended September 30, 2025, with no such impairment recorded in the same period of 2024[248]. Shareholder Returns - The quarterly dividend was reduced from $1.05 per share to $0.75 per share effective May 28, 2025[165]. - The Board reduced the quarterly common stock dividend from $1.05 per share to $0.75 per share on a split-adjusted basis to strengthen the balance sheet and support future growth[216]. - The company entered into a $350 million common stock repurchase program approved in August 2025, with no shares repurchased during the nine months ended September 30, 2025[173]. Market and Economic Conditions - The U.S. Federal Reserve lowered the Federal Funds Rate to a target range of 3.75% to 4.00% in October 2025, with the 10-Year U.S. Treasury yield at 4.15%[158]. - Healthcare wage inflation remains a concern, with increased labor costs due to reliance on higher-cost contract nursing labor[161]. Sustainability and Corporate Governance - The company is committed to sustainability and has a Board committee overseeing its sustainability efforts[152].

Revenue Performance - Third quarter 2025 revenue was $93 million, a decrease of 6.7% compared to $99 million in the same period last year[5][6]. - Organic revenue for the third quarter was $73 million, down 4.7% from $76 million year-over-year[8][6]. - Revenue for the three months ended September 30, 2025, was $92,571 thousand, a decrease of 6.7% compared to $99,237 thousand for the same period in 2024[27]. - For Q3 2025, total revenue was $92,571,000, a decrease of 6% from $99,237,000 in Q3 2024[39]. - For the nine months ended September 30, 2025, total revenue reached $283,280,000, a slight increase from $278,503,000 in the same period of 2024[39]. - For the full year 2025, revenue is projected to be between $367 million (down 3%) and $378 million (no change) compared to the previous year[41]. Profitability Metrics - Gross margin decreased to 37.3%, down 140 basis points from 38.7% in the prior year[10][6]. - Net income for the quarter was approximately $1 million, an increase of 3.6% compared to $0.2 million in the previous year[12][6]. - Adjusted EBITDA was $4 million, a decrease of $4 million from $7 million, marking the eighth consecutive quarter of positive Adjusted EBITDA[12][6]. - Gross profit for the nine months ended September 30, 2025, increased to $109,911 thousand, up from $105,890 thousand in 2024, reflecting a growth of 2.0%[27]. - Net income for the nine months ended September 30, 2025, was $7,883 thousand, compared to a net loss of $5,314 thousand for the same period in 2024[27]. - Adjusted EBITDA for the nine months ended September 30, 2025, was $18,068 thousand, compared to $17,317 thousand in 2024, representing an increase of 4.3%[38]. - The company reported a net income margin of 2.8% for the nine months ended September 30, 2025, compared to a net loss margin of 1.9% in 2024[38]. Cash and Assets - Cash and cash equivalents increased by $18 million to $71 million as of September 30, 2025, with no debt on the balance sheet[13][6]. - Total current assets as of September 30, 2025, were $216,158 thousand, an increase of 24.7% from $173,302 thousand in 2024[29]. - Cash and cash equivalents at the end of the period were $71,453 thousand, compared to $53,441 thousand at the end of September 30, 2024, reflecting a growth of 33.7%[31]. - Total liabilities decreased to $51,354 thousand as of September 30, 2025, down from $75,335 thousand in 2024, a reduction of 31.9%[29]. - Total stockholders' equity increased to $190,185 thousand as of September 30, 2025, up from $133,868 thousand in 2024, marking a growth of 42.0%[29]. Strategic Initiatives - The company announced the launch of Transformation 2.0, focusing on strategic growth areas and exiting lower margin categories, which accounted for 22% of revenue in Q3 2025[3][4]. - The updated full year 2025 revenue outlook is now projected to be in the range of -3% to flat, down from a prior outlook of 4% to 6%[14][6]. - The company expects full year 2025 Organic Revenue growth of 4-6%, excluding revenue from exited categories[14][6]. - The organic revenue outlook for 2025 is estimated to be between $292 million (up 4%) and $298 million (up 6%) from the previous year[41]. - Adjustments from category and channel exits for the full year 2025 are expected to be between $(75) million and $(80) million[41].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ GENELUX CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of Delaware 001-41599 77-0583529 Comm ...

Financial Performance - Revenues for Q3 2025 were $996 million, representing a year-over-year increase of 1.8%[140] - Net income for Q3 2025 was $57 million, with diluted net income per share of $0.78[140] - Total net revenues for Q3 2025 increased by $18 million compared to Q3 2024, driven by higher Clear Aligner volume[146] - Total income from operations for Q3 2025 was $96.3 million, down 40.7% from $162.3 million in Q3 2024, with an operating margin decrease from 16.6% to 9.7%[169] - Interest income for Q3 2025 was $3.2 million, down from $4.0 million in Q3 2024, representing 0.3% of net revenues[173][175] - Other income (expense), net for Q3 2025 was $(4.8) million, compared to $(0.4) million in Q3 2024, reflecting a decrease primarily due to foreign exchange rate changes[176][177] Revenue Breakdown - Clear Aligner revenues reached $806 million, up 2.4% year-over-year, with case volume increasing by 4.9%[140] - Imaging Systems and CAD/CAM services revenues were $190 million, a decrease of 0.6% year-over-year[140] - Clear Aligner net revenues increased by $19 million in Q3 2025 compared to Q3 2024, primarily due to increased volume and favorable foreign exchange rates[147] - Systems and Services net revenues decreased by $1 million in Q3 2025, primarily due to lower scanner system sales[149] Operational Metrics - Total case volume for Clear Aligner increased by 30.5 thousand cases, or 4.9%, in Q3 2025 compared to Q3 2024, reaching 647.8 thousand cases[145] - Clear Aligner average selling price (ASP) decreased, negatively impacting net revenues by $29 million in Q3 2025[147] - Clear Aligner segment income from operations for Q3 2025 was $250.7 million, down 9.3% from $276.3 million in Q3 2024, with an operating margin decrease from 35.1% to 31.1%[169][171] - Systems and Services segment income from operations for Q3 2025 was $59.8 million, a decrease of 12.9% from $68.7 million in Q3 2024, with an operating margin decrease from 36.0% to 31.5%[169][172] Expenses and Costs - The company anticipates restructuring expenses between $40 million and $50 million due to workforce reductions initiated in Q3 2025[136] - Research and development expenses increased by $8 million in Q3 2025 compared to Q3 2024, reflecting higher employee costs[162] - Selling, general and administrative expenses decreased by $16.3 million in Q3 2025 compared to Q3 2024, primarily due to lower employee costs[158] - Gross margin for Clear Aligner decreased to 64.9% in Q3 2025 from 70.3% in Q3 2024, impacted by restructuring charges and lower ASPs[151] - Total cost of net revenues increased by $60.4 million in Q3 2025 compared to Q3 2024, reflecting higher costs associated with Clear Aligner production[151] - Restructuring and other charges amounted to $31.8 million in Q3 2025, representing 3.2% of net revenues[165] Tax and Cash Position - The effective tax rate for Q3 2025 was 40.1%[140] - Provision for income taxes for Q3 2025 was $38.0 million, down from $50.0 million in Q3 2024, with an effective tax rate increase from 30.1% to 40.1%[179][181] - Cash and cash equivalents totaled $1,005 million as of September 30, 2025[140] - Cash and cash equivalents as of September 30, 2025, were $1,005 million, down from $1,044 million as of December 31, 2024, with $814 million held by foreign subsidiaries[183] - Net cash provided by operating activities for the nine months ended September 30, 2025, was $370.0 million, down from $452.2 million in the same period of 2024[185][186] Market and Economic Conditions - The geopolitical conflicts and macroeconomic conditions are expected to continue impacting consumer sentiment and demand for dental services[132] - Inflation has impacted both revenues and costs globally, with uncertainty regarding future inflation trends[202] Investments and Financial Instruments - As of September 30, 2025, the carrying value of investments in privately held companies was $198.2 million, up from $188.2 million at December 31, 2024[205] - The carrying value of investments in privately held companies is subject to equity price risks and macroeconomic volatility[203] - The company performs qualitative assessments at each reporting date to determine impairment triggers for its investments[205] - The company has no short-term or long-term marketable securities as of September 30, 2025[197] - The company does not use derivative financial instruments to manage exposure to changes in interest rates[198] - The company entered into foreign currency forward contracts primarily involving the Euro, British Pound, Chinese Yuan, Polish Zloty, and Canadian Dollar to mitigate foreign exchange risk[200] - A hypothetical 10% aggregate change in foreign currency exchange rates relative to the U.S. dollar could have a material impact on the company's results of operations and financial position[201] - The company’s financial performance is affected by fluctuations in foreign currency exchange rates due to its international operations[199]

Exhibit 99.1 QVC GROUP REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS West Chester, Pennsylvania, November 5, 2025 – QVC Group, Inc. ("QVC Group") (Nasdaq: QVCGA, QVCGP; OTCQB: QVCGB) today reported third quarter 2025 results . (1) THIRD QUARTER 2025 FINANCIAL RESULTS | | | | | | | % Change Constant | | | --- | --- | --- | --- | --- | --- | --- | --- | | (amounts in millions) | | 3Q25 | | 3Q24 | % Change | (a) Currency | | | Revenue | | | | | | | | | QxH | $ | 1,416 | $ | 1,521 | (7) % | | | | QVC Internation ...

Clinical Development - The company is progressing multiple product candidates through clinical development, including ARV-102 for neurodegenerative disorders and ARV-393 for non-Hodgkin lymphoma [120]. - The ongoing Phase 1 clinical trial of ARV-102 in patients with Parkinson's disease has completed the single ascending dose cohort and is progressing to multiple ascending doses [124]. - The company plans to present initial data from the multiple dose cohort of the Phase 1 clinical trial of ARV-102 in patients with Parkinson's disease in 2026 [133]. - The Phase 1 clinical trial of ARV-102 included a randomized, double-blind, placebo-controlled design to assess safety and pharmacodynamics [125]. - The company has received Clinical Trial Application approval in the Netherlands for the Phase 1 clinical trial of ARV-102 in patients with Parkinson's disease [124]. - The Phase 1 clinical trial of ARV-102 was well tolerated, with no serious adverse events reported among 15 patients treated [136]. - The Phase 1 clinical trial of ARV-393 in patients with relapsed/refractory NHL is ongoing, with multiple responses observed in early cohorts [140]. - The company intends to share updated clinical data from the ongoing Phase 1 trial of ARV-393 at a medical congress in 2026 [140]. - The company plans to initiate a Phase 1 clinical trial of ARV-393 in combination with glofitamab in patients with DLBCL in 2026 [139]. - The company plans to initiate a first-in-human Phase 1 clinical trial for ARV-027 in healthy volunteers in 2026, pending regulatory feedback [166]. Product Efficacy - ARV-102 demonstrated over 90% reduction of LRRK2 in peripheral blood mononuclear cells at single doses of 60 mg or greater [131]. - In the Phase 1 clinical trial of ARV-102, treatment resulted in median LRRK2 protein reductions of 86% with a 50 mg dose and 97% with a 200 mg dose in patients with Parkinson's disease [136]. - ARV-393 showed strong synergistic antitumor activity in preclinical models of aggressive diffuse large B-cell lymphoma when combined with standard of care chemotherapy [135]. - ARV-393 in combination with R-CHOP chemotherapy achieved complete tumor regressions in all treated mice, indicating significant tumor growth inhibition (TGI) compared to other treatments [137]. - In preclinical studies, ARV-393 demonstrated robust tumor growth inhibition (≥95%) in two patient-derived xenograft (PDX) models of transformed follicular lymphoma (tFL) and showed enhanced antitumor activity in combination with small molecule inhibitors [141]. - ARV-806, a novel PROTAC KRAS G12D degrader, exhibited in vitro potency approximately 25 times greater than existing KRAS inhibitors and 40 times greater than the leading clinical-stage degrader [143]. - ARV-806 achieved over 90% degradation of KRAS G12D for seven days in a colorectal tumor xenograft model, indicating sustained pharmacodynamic activity [146]. - Vepdegestrant demonstrated near-complete ER degradation in tumor cells and superior anti-tumor activity compared to fulvestrant in preclinical studies [149]. Financial Performance - The company has raised approximately $1.7 billion in gross proceeds since inception through September 30, 2025, and received $913.1 million from collaboration partners and licensing arrangements [170]. - Revenue for Q3 2025 was $41.9 million, a decrease of $60.5 million from $102.4 million in Q3 2024, primarily due to reduced revenue from Novartis agreements [224]. - For the nine months ended September 30, 2025, revenue totaled $253.1 million, an increase of $48.9 million compared to $204.2 million in the same period of 2024, driven by a $157.9 million increase from the Vepdegestrant collaboration with Pfizer [225]. - The company recognized $20.0 million in revenue during the three months ended September 30, 2025, upon achieving a development milestone under the Novartis License Agreement [192]. - The company has not generated any revenue from product sales and does not expect to do so in the near future, relying instead on research collaborations and licensing arrangements [179]. Expenses and Cost Management - Research and development expenses for the three months ended September 30, 2025, totaled $64.7 million, a decrease of 25.5% compared to $86.9 million for the same period in 2024 [205]. - Total program-specific external expenses for the nine months ended September 30, 2025, were $89.2 million, down from $101.7 million in 2024, reflecting a decrease of 12.4% [205]. - The total unallocated internal expense for research and development was $24.4 million for the three months ended September 30, 2025, compared to $39.2 million in 2024, a decrease of 37.5% [205]. - General and administrative expenses for Q3 2025 totaled $21.0 million, a decrease of $54.8 million from $75.8 million in Q3 2024, mainly due to a loss on lease termination [230]. - The company expects to achieve annual operating cost savings of $100 million on a run-rate basis following workforce reductions [175]. - The company announced a workforce reduction of approximately 33% in April 2025 and an additional 15% in September 2025 to streamline operations [172][174]. Collaborations and Agreements - The collaboration agreement with Pfizer includes an upfront payment of $650 million and potential contingent payments of up to $1.4 billion based on regulatory and sales milestones [181]. - The Vepdegestrant (ARV-471) Collaboration Agreement allows for shared research and development expenses with Pfizer, which have been equal since July 22, 2021 [206]. - The Novartis Transaction resulted in a one-time upfront payment of $150.0 million and potential contingent payments of up to $1.01 billion based on specified milestones for luxdegalutamide (ARV-766) [192]. - The Bayer Collaboration Agreement was terminated effective August 12, 2024, after receiving a total of $29.5 million in upfront and additional payments [197][196]. - The company is eligible to receive up to $225.0 million in development milestone payments and up to $550.0 million in sales-based milestone payments under the Pfizer Research Collaboration Agreement [188]. Tax and Cash Management - As of December 31, 2024, the company had $111.0 million in federal net operating loss carryforwards, which can be carried forward indefinitely, subject to an 80% limit on taxable income [213]. - The company has provided a valuation allowance against deferred tax assets, indicating that it is more likely than not that the benefits will not be realized based on its earnings history [214]. - Cash, cash equivalents, and marketable securities amounted to $787.6 million as of September 30, 2025, compared to $1.0 billion as of December 31, 2024 [243]. - Net cash used in operating activities for the nine months ended September 30, 2025, increased by $68.2 million to $(243.4) million, primarily due to a $187.6 million decrease in deferred revenue [246]. - The company anticipates that its cash, cash equivalents, and marketable securities will fund its planned operating expenses into the second half of 2028 [252].

Exhibit 99.1 QVC GROUP REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS West Chester, Pennsylvania, November 5, 2025 – QVC Group, Inc. ("QVC Group") (Nasdaq: QVCGA, QVCGP; OTCQB: QVCGB) today reported third quarter 2025 results . (1) "We are early in our WIN growth plan but continue to make progress. We reduced the year-over-year rate of revenue decline in our QxH segment despite the decline in linear television viewership, driven by revenue growth in our social and streaming platforms." said David Rawlinson, P ...

Financial Performance - The company reported a net loss of $18.3 million, or ($0.15) per diluted share, while EBITDAX was $139.9 million, or $1.01 per diluted share [5]. - Total operating revenues for Q3 2025 were $188.862 million, a decrease of 30.5% compared to $271.578 million in Q3 2024 [29]. - Crude oil sales in Q3 2025 were $190.773 million, down from $270.636 million in Q3 2024, reflecting a decline of 29.5% [29]. - For the three months ended September 30, 2025, HighPeak Energy reported a net loss of $18.335 million compared to a net income of $49.933 million for the same period in 2024, representing a significant decline [35]. - The diluted net loss per share attributable to common shareholders was $0.15 for Q3 2025, compared to earnings of $0.35 per share in Q3 2024 [35]. - EBITDAX for the three months ended September 30, 2025, was $139.852 million, down from $214.341 million in the same period of 2024, indicating a decrease of approximately 34.7% [37]. - Discretionary cash flow for the three months ended September 30, 2025, was $105.376 million, compared to $176.374 million for the same period in 2024, reflecting a decline of about 40.2% [38]. - Net cash provided by operating activities for the three months ended September 30, 2025, was $120.239 million, down from $177.103 million in Q3 2024, a decrease of approximately 32.2% [38]. - The company reported a free cash flow of $1.572 million for Q3 2025, a significant drop from $28.135 million in Q3 2024 [38]. - The company reported a total of $418.504 million in net cash provided by operating activities for the nine months ended September 30, 2025, compared to $550.873 million for the same period in 2024, a decrease of 24% [31]. Operational Highlights - HighPeak's average sales volumes for Q3 2025 were 47.8 MBoe/d, with approximately 66% being crude oil and 83% liquids [3]. - The company drilled 6 gross (6.0 net) horizontal wells and turned-in-line 9 gross (8.9 net) producing wells during Q3 2025 [4]. - The company picked up a second drilling rig in early October and completed its second simul-frac operation on a six well pad [6]. - Lease operating expenses averaged $6.57 per Boe, consistent with the first half of 2025 [5]. Capital Expenditures and Debt Management - Capital expenditures for Q3 2025 totaled $86.6 million, a reduction of over 30% compared to Q2 2025 [5]. - The company extended all debt maturities to September 2028 and increased liquidity by over $170 million [5]. - Interest expense for the three months ended September 30, 2025, was $37.150 million, compared to $42.579 million in the same period of 2024, showing a decrease of about 12.8% [37]. - The company incurred a loss on extinguishment of debt amounting to $25.437 million in Q3 2025, which contributed positively to adjusted net income calculations [40]. Asset and Equity Position - Total assets increased to $3.205 billion as of September 30, 2025, compared to $3.063 billion as of December 31, 2024, representing a growth of 4.6% [27]. - Current liabilities decreased significantly to $152.693 million from $284.630 million, a reduction of 46.3% [27]. - Total stockholders' equity rose to $1.627 billion as of September 30, 2025, compared to $1.602 billion as of December 31, 2024, an increase of 1.6% [27]. - Cash and cash equivalents increased to $164.913 million at the end of Q3 2025, up from $86.649 million at the beginning of the period, an increase of 90% [30]. Management and Strategic Focus - HighPeak appointed Michael Hollis as permanent CEO and Jason Edgeworth as Chairman of the Board in November 2025 [5]. - The company plans to focus on operational efficiencies and cost management strategies to navigate the current market challenges and improve future performance [42]. Pricing and Market Conditions - The average realized price for crude oil was $65.63 per Bbl, resulting in an overall realized price of $42.91 per Boe, or 66% of the weighted average NYMEX crude oil prices [8]. - Average realized price for crude oil per Bbl in Q3 2025 was $65.63, down from $75.99 in Q3 2024, a decrease of 13.1% [33]. - Average daily crude oil sales volumes decreased to 31,594 Bbls in Q3 2025 from 38,710 Bbls in Q3 2024, a drop of 18.5% [33].

Financial Performance - Revenue decreased 31% year-over-year to $61.6 million[6] - GAAP gross profit decreased 8% year-over-year to $22.8 million[6] - Adjusted gross profit decreased 4% year-over-year to $36.1 million, with adjusted gross profit margin increasing to 59% from 42% year-over-year[6] - GAAP net loss improved 28% year-over-year to $22.0 million[6] - Adjusted EBITDA decreased 4% year-over-year to $9.9 million[6] - For the three months ended September 30, 2025, the net loss was $22.0 million, an improvement from a net loss of $30.6 million in the same period of 2024[20] - Adjusted EBITDA for Q3 2025 was $9.9 million, slightly down from $10.3 million in Q3 2024[20] - The company incurred $2.0 million in acquisition and restructuring costs in Q3 2025, compared to $8.1 million in Q3 2024, indicating a reduction in restructuring expenses[20] - Interest expense decreased to $7.1 million in Q3 2025 from $8.0 million in Q3 2024, reflecting improved debt management[20] - Depreciation and amortization expenses were $20.8 million in Q3 2025, slightly up from $20.1 million in Q3 2024[20] - Stock-based compensation and distributions to members decreased to $2.8 million in Q3 2025 from $3.8 million in Q3 2024, indicating cost control measures[20] - The income tax benefit for Q3 2025 was $(0.5) million, compared to a benefit of $0.6 million in Q3 2024[20] - Non-cash revaluation of warrant liability resulted in a loss of $(0.1) million in Q3 2025, compared to a gain of $0.3 million in Q3 2024[20] - Other expenses were $(0.2) million in Q3 2025, with no other expenses reported in Q3 2024[20] - The company continues to focus on improving its financial metrics and reducing losses while managing operational costs effectively[20] Market Expansion and Product Development - CouponFollow.com expanded into the European market with localized coupon content in Germany, France, and Poland[7] - MapQuest launched redesigned apps on iOS and Android, enhancing user features[7] - Startpage.com released Vanish Private AI Chat, ensuring user privacy with no logging of IP addresses or queries[7] Future Guidance and Uncertainty - System1 does not plan to provide financial guidance for Q4 2025 due to uncertainty with a key advertising partner[5] Asset Management - Total assets decreased to $385.2 million from $459.1 million as of December 31, 2024[18]